Ads
related to: who makes keytruda cancer drug
Search results
Merck Reaches $1.3 Billion Deal for Eye-Drug Company EyeBio
The Wall Street Journal· 14 hours agoIn recent years, Chief Executive Rob Davis has been doing deals to lessen Merck’s reliance on the...
Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence - Merck & Co...
Benzinga· 17 hours agoMerck & Co., Inc. MRK is reportedly on the verge of acquiring EyeBio, an eye drug company, for a sum...
Merck to Buy Eye Drug Company Eyebiotech for Up to $3 Billion. It’s Doubling Down on Deals.
Barrons.com· 13 hours agoThe pharmaceutical company agrees to buy eye drug company Eyebiotech for up to $3 billion as it...
Merck to pay as much as $3 billion for eye treatment startup
Crain's New York Business· 11 hours agoWhile it raised its profit and sales forecast for the year on Keytruda sales, Merck has been on the...
Anti-Cancer Drug Pembrolizumab: Frequently Used Alone Or With Other Treatments
Forbes· 3 days agoPembrolizumab, sold as Keytruda by Merck & Co., was one of the first inhibitors to hit the market. A...
ASCO24: An early look at cancer drug study results
BioPharma Dive via Yahoo Finance· 6 days agoClinical trial abstracts posted Thursday ahead of this year’s ASCO meeting give a peek at anticipated datasets from Immunocore, Merus, J&J and Merck &...
Roche’s Sabry retires; Duchenne drug fails confirmatory test
BioPharma Dive via Yahoo Finance· 2 days agoThe veteran executive will be replaced by Boris Zaïtra. Elsewhere, Nippon Shinyaku shared negative...
News Highlights: Top Company News of the Day - Wednesday at 5 AM ET
Morningstar· 16 hours agoBHP Seeks Another Extension to $50 Billion Takeover Talks With Anglo American BHP said a further deadline extension is needed before it can reach an agreement with Anglo American on a $50 billion takeover of its London-based rival. Royal Mail
TME Pharma Announces Convocation of the 2024 Annual General Meeting of Shareholders
Morningstar· 3 days agoTME Pharma N.V. (Euronext Growth Paris: ALTME) (Paris:ALTME),a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment ...
Billionaire Ken Griffin Is Buying These Dividend Stocks Hand Over Fist. Should You?
Motley Fool via Yahoo Finance· 6 days agoThe company picked up new U.S. and European approvals for blockbuster drug Keytruda. It announced...
Ad
related to: who makes keytruda cancer drug
